

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5208379

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	CANCER RESEARCH TECHNOLOGY LIMITED	06/17/2015
RECEIVING PARTY DATA		
Name:	ASTRAZENECA AB	
Street Address:	SE-151 85	
City:	SODERTALJE	
State/Country:	SWEDEN	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16025455
CORRESPONDENCE DATA		
Fax Number:	(301)398-9306	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	3013980000	
Email:	patents@astrazeneca.com	
Correspondent Name:	ASTRAZENECA MEDIMMUNE	
Address Line 1:	ONE MEDIMMUNE WAY	
Address Line 4:	GAITHERSBURG, MARYLAND 20878	
ATTORNEY DOCKET NUMBER:	200230-US-CNT	
NAME OF SUBMITTER:	AUDREY CLARK	
SIGNATURE:	/Audrey Clark/	
DATE SIGNED:	10/26/2018	
Total Attachments: 3		
source=2015_06_17_executed_CRTL_to_AZAB#page1.tif		
source=2015_06_17_executed_CRTL_to_AZAB#page2.tif		
source=2015_06_17_executed_CRTL_to_AZAB#page3.tif		

ASSIGNMENT OF PATENT RIGHTS

This Assignment of Patent Rights (this "**Assignment**") is made as of the 30th day of May 2015 (the "**Effective Date**") by and between

- (1) CANCER RESEARCH TECHNOLOGY LIMITED a company whose registered office is at Angel Building, 407 St John Street, London England, EC1V 4AD (the "**Assignor**") and
- (2) ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482 with registered office address at SE-151 85 Södertälje, Sweden jointly with CANCER RESEARCH TECHNOLOGY LIMITED (together the "**Assignee**")

Recitals

- (A) WHEREAS the Assignor has agreed to assign to the Assignee the Assignor's entire right, title and interest in and to the patent application(s) identified in the attached Schedule (the "**Patent Application(s)**") and in and to the inventions and improvements disclosed in such Patent Application(s).
- (B) WHEREAS, the Parties are party to an alliance agreement dated 18th December 2009 (as amended) which is intended to apply to revenue sharing from the **Patent Rights** and **Subsequent Patents** (as defined below).

Agreement

NOW, THEREFORE, it is hereby agreed as follows:

1. Assignment

In consideration of the payment by Assignee to Assignor of the sum of £1, the receipt of which is hereby acknowledged, Assignor hereby assigns, sells and transfers to Assignee, with full title guarantee free from all and any charges or other third party rights, the following rights (the "**Patent Rights**") such that the Patent Rights shall be owned jointly by AstraZeneca AB and Cancer Research Technology Limited:

- 1.1 all of Assignor's entire right, title and interest in and to the Patent Application(s), any rights under the International Convention for the Protection of Industrial Property and all other applicable treaties and conventions, any rights of priority with respect to the Patent Application(s), including any divisional, continuation and continuation-in-part applications claiming, directly or indirectly, the benefit of, or priority to, any of the Patent Application(s) (and equivalents in countries other than the United States), any patents in any country that may be granted to or on any of the foregoing applications ("**Subsequent Patents**"), any reissues, re-examinations or extensions of such Subsequent Patents (and equivalents in countries other than the United States), to the full end of the term for which the Subsequent Patents have been granted, reissued, re-examined or extended;
- 1.2 all of Assignor's entire right, title and interest in and to the inventions and improvements disclosed in the Subsequent Patents and Patent Application(s); and

- 1.3 any and all causes of action, claims, demands or other rights occasioned from or because of any and all past and future infringement of any of the Subsequent Patents or Patent Application(s), including all rights to recover damages, profits and injunctive relief for infringement of any of the Subsequent Patents or Patent Application(s).

2 Further Action

Assignor agrees, at the reasonable request of Assignee: (a) to execute and deliver any further documents and to take any further actions reasonably necessary to enable Assignee to become the registered owner of the Patent Rights and to secure the benefits of the rights hereby assigned; and (b) to aid in securing and maintaining patent protection for the Patent Rights throughout the world, including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.

3 Recordation

Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

4 Governing Law and Jurisdiction

The interpretation and construction of this Agreement shall be governed by the laws of England and Wales and the Assignor and Assignee hereby submit to the exclusive jurisdiction of the English courts for any action, suit or proceeding arising out of or relating to this Agreement.

THIS ASSIGNMENT IS EXECUTED by the authorised representatives of the parties as of the date first written above.

Signed at: Cambridge, England

Date: 17th June 2015

Signed for and on behalf of
Cancer Research Technology Limited

Signature: [Signature]

Name: KEITH BLUNDY

Title: CEO

Witnessed by: [Signature]

Name: EDWINA JESSE

Signed at: Cheshire, England

Date: 20th June 2015

Signed for and on behalf of **ASTRAZENECA AB (PUBL)**

Signature: [Signature]

Name: Lucy PADGET

Title: Authorised Signatory

Witnessed by: [Signature]

Name: Jennifer Pennington

THE SCHEDULE

THE PATENT APPLICATION(S)					
AstraZeneca Case No:	Application Ref:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
200230-AR-NP	A	Argentina	National	20150101720	29th May 2015
200230-BO-NP	B	Bolivia	National	SP 00103-2015	29th May 2015
200230-ET-NP	C	Ethiopia	National	1, 3, 4-Thiadiazole Compounds and Their Use in Treating Cancer	To be advised
200230-WO-PCT	D	International	PCT	PCT/GB2015/051537	27th May 2015
200230-LB-NP	E	Lebanon	National	10663	29th May 2015
200230-PY-NP	F	Paraguay	National	23439/2015	29th May 2015
200230-PK-NP	G	Pakistan	National	1, 3, 4-Thiadiazole Compounds and Their Use in Treating Cancer	To be advised
200230-TW-NP	H	Taiwan	National	1, 3, 4-Thiadiazole Compounds and Their Use in Treating Cancer	29th May 2015
200230-UY-NP	I	Uruguay	National	36.145	28th May 2015
200230-VE-NP	J	Venezuela	National	1, 3, 4-Thiadiazole Compounds and Their Use in Treating Cancer	To be advised
200230-BS-NP	K*	Bahamas	National	1, 3, 4-Thiadiazole Compounds and Their Use in Treating Cancer	To be advised
200230-JM-NP	L*	Jamaica	National	18/1/5675	18th May 2015

Patent Application(s) referenced A to J inclusive claim priority from the following GB Application(s)

Application No.	Filing Date
1409624.2	30th May 2014

Patent Application(s) referenced K* and L* do not claim priority